Summary

Antibiotics Market Summary

The global antibiotics market size was estimated at USD 53.07 billion in 2024 and is projected to reach USD 74.07 billion by 2033, growing at a CAGR of 3.71% from 2025 to 2033, major factor contributing to market growth. The antibiotics market is driven by the prevalence of bacterial infections.

Respiratory tract infections (RTIs), such as pneumonia and bronchitis, are among the most widespread, for instance, in May 2025, the CDC estimated that the U.S. experienced between 47-82 million flu illnesses, 21 million medical visits, and 640,000 hospitalizations, based on data from 2024 - 2025. These preliminary figures, derived from weekly influenza surveillance and mathematical modeling, reflect the season's disease burden, often leading to secondary bacterial infections requiring antibiotics. Urinary tract infections (UTIs) follow closely, with over 150 million cases annually worldwide, according to BMC Infectious Diseases, making them a leading cause of antibiotic use. Skin and soft tissue infections (SSTIs), such as cellulitis, are also significant, especially in outpatient care. Hospital-acquired infections (HAIs), including Clostridium difficile and methicillin-resistant Staphylococcus aureus (MRSA), further increase demand. These infections are fueled by urbanization, aging populations, and rising antimicrobial resistance (AMR), which reduces the efficacy of existing treatments. High infection rates in developing regions with limited healthcare access further amplify the need for antibiotics, sustaining market growth despite resistance challenges.

Research and development (R&D) in antibiotics face hurdles due to high costs and low profitability. Developing new antibiotics is expensive, with clinical trials and regulatory demands adding to the burden, while short treatment durations limit returns. However, initiatives such as in April 2025, CARB-X awarded ArrePath USD 3.7 million to develop a novel antibiotic targeting multidrug-resistant Enterobacterales, focusing on complicated urinary tract infections. Using an AI-driven platform, ArrePath identified inhibitors with a unique mechanism, potentially offering oral and IV treatment options to combat antimicrobial resistance effectively. For example, Pfizer partnered with AbbVie in 2023 to develop novel antibiotic combinations, sharing costs and risks. The Global AMR R&D Hub also coordinates international efforts to bolster the antibiotic pipeline. Despite these measures, challenges persist, as resistance develops quickly, reducing the lifespan of new drugs. Sustained public-private collaboration is critical to overcoming these barriers and ensuring the development of effective antibiotics to combat rising resistance.

Key players in the antibiotics market employ strategies such as mergers, partnerships, and innovation to stay competitive. In February 2025, key biotech deals included Novartis acquiring Anthos Therapeutics for up to $2.15 billion ($925 million upfront) for its stroke prevention program, Eli Lilly buying Organovo’s FXR program for inflammatory bowel disease (terms undisclosed), and the merger of Alumis and Acelyrin, focusing on immune-mediated diseases with a $737 million cash runway. In 2023, Merck invested over USD 674 million partnering with Exscientia to apply AI in drug development, manufacturing, and regulatory processes. Additionally, Merck joined forces with BenevolentAI, investing hundreds of millions more in AI drug discovery platforms. Smaller firms like Entasis Therapeutics, which gained FDA approval for Xacduro in 2023 for pneumonia, target niche markets. Companies such as GSK also promote antibiotic stewardship to encourage responsible use. However, generic competition and the need for constant innovation amid resistance pressures challenge profitability. These developments reflect a dynamic market where firms balance cost management with the pursuit of novel antibiotics to maintain their edge.

Global Antibiotics Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global antibiotics market report on the basis of drug class, type, action mechanism, and region:

• Drug Class Outlook (Revenue in USD Million, 2021 - 2033)
• Cephalosporin
• Penicillin
• Fluoroquinolone
• Macrolides
• Carbapenems
• Aminoglycosides
• Sulfonamides
• 7-ACA
• Others
• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Branded Antibiotics
• Generic Antibiotics
• Action Mechanism Outlook (Revenue, USD Million, 2021 - 2033)
• Cell Wall Synthesis Inhibitors
• Protein Synthesis Inhibitors
• DNA Synthesis Inhibitors
• RNA Synthesis Inhibitors
• Mycolic Acid Inhibitors
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
o U.S.
o Canada
o Mexico
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Denmark
o Sweden
o Norway
• Asia Pacific
o China
o Japan
o India
o Australia
o Thailand
o South Korea
• Latin America
o Brazil
o Argentina
• Middle East & Africa
o South Africa
o Saudi Arabia
o UAE
o Kuwait

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug Class
1.2.2. Type
1.2.3. Action Mechanism
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug Class
2.2.2. Type
2.2.3. Action Mechanism
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Antibiotics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Development of advanced products
3.2.1.2. Increasing prevalence of infectious diseases
3.2.1.3. Growing collaborations for development of antibiotics
3.2.2. Market restraint analysis
3.2.2.1. High number of patent expirations
3.2.2.2. High R&D cost
3.3. Antibiotics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Antibiotics Market: Drug Class Estimates & Trend Analysis
4.1. Drug Class Market Share, 2024 & 2033
4.2. Segment Dashboard
4.3. Global Antibiotics Market by Drug Class Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
4.4.1. Cephalosporin
4.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.2. Penicillin
4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.3. Fluoroquinolone
4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.4. Macrolides
4.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.5. Carbapenems
4.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.6. Aminoglycosides
4.4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.7. Sulfonamides
4.4.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.8. 7-ACA
4.4.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.9. Others
4.4.9.1. Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. Antibiotics Market: Type Estimates & Trend Analysis
5.1. Type Market Share, 2024 & 2033
5.2. Segment Dashboard
5.3. Global Antibiotics Market by Type Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
5.4.1. Branded Antibiotics
5.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.4.2. Generic Antibiotics
5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. Antibiotics Market: Action Mechanism Estimates & Trend Analysis
6.1. Action Mechanism Market Share, 2024 & 2033
6.2. Segment Dashboard
6.3. Global Antibiotics Market by Action Mechanism Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
6.4.1. Cell Wall Synthesis Inhibitors
6.4.1.1. Market estimates and forecasts 2021 to 2033 (USD million)
6.4.2. Protein Synthesis Inhibitors
6.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
6.4.3. DNA Synthesis Inhibitors
6.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
6.4.4. RNA Synthesis Inhibitors
6.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
6.4.5. Mycolic Acid Inhibitors
6.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
6.4.6. Others
6.4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. Antibiotics Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2024 & 2033
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
7.5. North America
7.5.1. U.S.
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
7.5.2. Canada
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
7.5.3. Mexico
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
7.6. Europe
7.6.1. UK
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
7.6.2. Germany
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
7.6.3. France
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework/ reimbursement structure
7.6.3.3. Competitive scenario
7.6.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
7.6.4. Italy
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework/ reimbursement structure
7.6.4.3. Competitive scenario
7.6.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
7.6.5. Spain
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework/ reimbursement structure
7.6.5.3. Competitive scenario
7.6.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
7.6.6. Norway
7.6.6.1. Key country dynamics
7.6.6.2. Regulatory framework/ reimbursement structure
7.6.6.3. Competitive scenario
7.6.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
7.6.7. Sweden
7.6.7.1. Key country dynamics
7.6.7.2. Regulatory framework/ reimbursement structure
7.6.7.3. Competitive scenario
7.6.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
7.6.8. Denmark
7.6.8.1. Key country dynamics
7.6.8.2. Regulatory framework/ reimbursement structure
7.6.8.3. Competitive scenario
7.6.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
7.7. Asia Pacific
7.7.1. Japan
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
7.7.2. China
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
7.7.3. India
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
7.7.4. Australia
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
7.7.5. South Korea
7.7.5.1. Key country dynamics
7.7.5.2. Regulatory framework/ reimbursement structure
7.7.5.3. Competitive scenario
7.7.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
7.7.6. Thailand
7.7.6.1. Key country dynamics
7.7.6.2. Regulatory framework/ reimbursement structure
7.7.6.3. Competitive scenario
7.7.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
7.8. Latin America
7.8.1. Brazil
7.8.1.1. Key country dynamics
7.8.1.2. Regulatory framework/ reimbursement structure
7.8.1.3. Competitive scenario
7.8.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
7.8.2. Argentina
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework/ reimbursement structure
7.8.2.3. Competitive scenario
7.8.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
7.9. MEA
7.9.1. South Africa
7.9.1.1. Key country dynamics
7.9.1.2. Regulatory framework/ reimbursement structure
7.9.1.3. Competitive scenario
7.9.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
7.9.2. Saudi Arabia
7.9.2.1. Key country dynamics
7.9.2.2. Regulatory framework/ reimbursement structure
7.9.2.3. Competitive scenario
7.9.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
7.9.3. UAE
7.9.3.1. Key country dynamics
7.9.3.2. Regulatory framework/ reimbursement structure
7.9.3.3. Competitive scenario
7.9.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
7.9.4. Kuwait
7.9.4.1. Key country dynamics
7.9.4.2. Regulatory framework/ reimbursement structure
7.9.4.3. Competitive scenario
7.9.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2024
8.3.4. AbbVie, Inc.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Pfizer Inc.
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Novartis AG
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Merck & Co., Inc.
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Teva Pharmaceutical Industries Ltd.
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Lupin Pharmaceuticals, Inc.
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Viatris, Inc.
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Melinta Therapeutics LLC
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. Cipla, Inc.
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
8.3.13. Shionogi & Co., Ltd.
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Product benchmarking
8.3.13.4. Strategic initiatives
8.3.14. KYORIN Pharmaceutical Co., Ltd.
8.3.14.1. Company overview
8.3.14.2. Financial performance
8.3.14.3. Product benchmarking
8.3.14.4. Strategic initiatives
8.3.15. GSK plc
8.3.15.1. Company overview
8.3.15.2. Financial performance
8.3.15.3. Product benchmarking
8.3.15.4. Strategic initiatives
8.3.16. Nabriva Therapeutics PLC
8.3.16.1. Company overview
8.3.16.2. Financial performance
8.3.16.3. Product benchmarking
8.3.16.4. Strategic initiatives